HIV CLINICAL TRIALS MARKET SIZE AND SHARE ANALYSIS - GROWTH TRENDS AND FORECASTS (2024-2031)

Regional Analysis

To learn more about this report, Request sample copy

Dominating Region- North America

North America dominates the HIV clinical trials market with an estimated market share of 39.2% in 2024, due to presence of major pharmaceutical companies like AbbVie Inc. and Johnson & Johnson and contract research organizations (CROs) in the region. The region also has a supportive regulatory environment and high healthcare expenditure which promotes clinical research activities.

Fastest-Growing Region- Asia Pacific

Asia Pacific region exhibits the fastest growth and is emerging as a key market for HIV clinical trials. This can be attributed to rising investment by international players to leverage low-cost opportunities and growing patient population in countries like China and India. Regional governments are also encouraging clinical research to improve medical capabilities.

HIV Clinical Trials Market Outlook for Key Countries

U.S.- Leading Hub for HIV Clinical Trials and Innovation

The U.S. HIV clinical trials market leads due to top sponsors and trial sites. For instance, in September 2023, a Phase 1 trial for the novel HIV vaccine VIR-1388 began in the U.S. and South Africa. Funded by the National Institute of Allergy and Infectious Diseases (NIAID) and sponsored by Vir Biotechnology, the trial aims to test the safety and immune response of the vaccine, enrolling 95 HIV-negative participants.

Canada- Growing Healthcare Infrastructure Drives HIV Clinical Trials

The HIV clinical trials market in Canada is driven by increasing number of clinical trials and sites, along with the country’s robust healthcare infrastructure for conducting these trials. Furthermore, ongoing research and development, product innovation, and approvals are anticipated to boost the market growth. For instance, in April 2022, according to the government of Canada, approximately 77% of biopharmaceutical products are in the early stages of research and development (from research to phase I/II) In Canada, while 23% are in the mid- to late-stage of development (late-stage clinical trials). These government initiatives are expected to drive market expansion.

India- Cost-Effective and Diverse Patient Pool Boosting HIV Clinical Trials

The HIV clinical trials market in India is fueled by cost-effectiveness, a diverse patient population that makes it an appealing location for clinical trials, and growing research activities by organizations. For instance, in October 2023, Roche Pharma launched the Clinical Trial Excellence Project in India. The project aims to enhance the capabilities of public health institutions to conduct clinical trials and drug research. It will transform government hospitals into centers of excellence for clinical research, further, boosting the market.